MENU
+Compare
HALO
Stock ticker: NASDAQ
AS OF
May 13, 04:09 PM (EDT)
Price
$49.50
Change
-$17.08 (-25.65%)
Capitalization
8.12B

HALO stock forecast, quote, news & analysis

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more

Industry: #Biotechnology
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for HALO with price predictions
May 12, 2025

HALO saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for HALO moved out of overbought territory on May 12, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 61 similar instances where the indicator exited the overbought zone. In of the 61 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HALO moved out of overbought territory on May 08, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HALO broke above its upper Bollinger Band on May 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 30, 2025. You may want to consider a long position or call options on HALO as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HALO just turned positive on April 28, 2025. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

HALO moved above its 50-day moving average on May 07, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HALO crossed bullishly above the 50-day moving average on May 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 291 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.007) is normal, around the industry mean (14.767). P/E Ratio (17.707) is within average values for comparable stocks, (65.482). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.018). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (7.911) is also within normal values, averaging (254.233).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.15B. The market cap for tickers in the group ranges from 151 to 296.96B. NONOF holds the highest valuation in this group at 296.96B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was -8%. CTMX experienced the highest price growth at 122%, while NCNA experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 2%. For the same stocks of the Industry, the average monthly volume growth was 15% and the average quarterly volume growth was 68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 63
SMR Rating: 90
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com